Artificial neural networks in urology: Update 2000

Artificial neural networks (ANNs) are widely available and have been demonstrated to be superior to standard empirical methods of detecting, staging and monitoring prostate cancer. These algorithms have been statistically validated in diverse, well-characterized patient groups and are now being evaluated for clinical use worldwide. New variables based on demographic data, tissue and serum markers show promise for improving our ability to predict disease extent and outcome and may be integrated in future ANN models. This review focuses on recently developed neural networks for detecting, staging and monitoring prostate cancer.

[1]  R W Veltri,et al.  Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. , 1994, Journal of cellular biochemistry. Supplement.

[2]  W. Catalona,et al.  Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. , 1994, The Journal of urology.

[3]  I. Ikeda,et al.  Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. , 1996, British journal of urology.

[4]  J. Oesterling,et al.  Update on the appropriate staging evaluation for newly diagnosed prostate cancer. , 1997, The Journal of urology.

[5]  Z. Zhang,et al.  Evaluation of prostAsure index in the detection of prostate cancer: a preliminary report. , 1998, Urology.

[6]  A. Tewari,et al.  Novel staging tool for localized prostate cancer: a pilot study using genetic adaptive neural networks. , 1998, The Journal of urology.

[7]  R. Veltri,et al.  The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis. , 1998, Seminars in urologic oncology.

[8]  D. Bostwick,et al.  Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen , 1998, Cancer.

[9]  S. Groshen,et al.  Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. , 1998, Journal of the National Cancer Institute.

[10]  D. Bostwick,et al.  Microvessel density in prostate cancer: prognostic and therapeutic utility. , 1998, Seminars in urologic oncology.

[11]  C. Mantzoros,et al.  Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. , 1998, Journal of the National Cancer Institute.

[12]  J. Epstein,et al.  E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. , 1999, Urology.

[13]  EVALUATION OF AN ARTIFICIAL NEURAL NETWORK FOR THE DETERMINATION OF THE PROBABILITY OF PROSTATE CANCER PRIOR TO BIOPSY , 1999 .

[14]  R. Vessella,et al.  Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. , 1999, Urology.

[15]  A. Partin,et al.  Comparison of clinical staging algorithms and 111Indium‐capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients , 1999, Cancer.

[16]  J. Moul.  Angiogenesis, p53, bcl-2 and Ki-67 in the Progression of Prostate Cancer after Radical Prostatectomy , 1999, European Urology.

[17]  R W Veltri,et al.  Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. , 1999, Urology.

[18]  ARTIFICIAL INTELLIGENCE SYSTEM IN PREDICTION OF LYMPH NODE INVOLVEMENT IN RADICAL PROSTATECTOMY PATIENTS , 1999 .

[19]  A. Partin,et al.  Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4‐216) recognizes nucleophosmin/B23 , 1999, The Prostate.

[20]  M. Menon,et al.  Genetic Adaptive neuralnetwork Model to predict PSA progression following radical prostatectomy: A multi-institutional study , 1999 .

[21]  David M. Rodvold.  A software development process model for artificial neural networks in critical applications , 1999, IJCNN'99. International Joint Conference on Neural Networks. Proceedings (Cat. No.99CH36339).

[22]  Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation. , 1999, Urology.

[23]  M. Menon,et al.  Genetic adaptive neuralnetwork model to predict outcome of needle biopsy in 3773 patients with elevated PSA , 1999 .

[24]  Mattfeldt,et al.  Prediction of prostatic cancer progression after radical prostatectomy using artificial neural networks: a feasibility study , 1999, BJU international.

[25]  Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. , 1999, Cancer.